Denali regains full rights to DNL593 after Takeda terminates collaboration

Denali Therapeutics Inc.

Takeda terminated co-development agreement for DNL593 (PTV:PGRN) effective 60 days from April 3, 2026; reason is strategic, not safety/efficacy.
Denali will continue Phase 1/2 study independently; results expected by end of 2026.
Enrollment complete with 40 FTD-GRN participants; interim data showed dose-dependent CSF progranulin increases and favorable tolerability.
Denali has no further financial obligations to Takeda post-termination and retains full intellectual property rights.
DNL593 uses TransportVehicle platform, first FDA-approved BBB-crossing technology, addressing FTD-GRN with no approved slowing treatments.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Denali Therapeutics Inc. terminated Collaboration Agreement with Takeda Pharmaceutical Company Limited (effective 2018-01-03).

Action: termination
Agreement: collaboration
Counterparty: Takeda Pharmaceutical Company Limited
Effective: 2018-01-03

Exact text from the filing

On April 3, 2026, Denali Therapeutics Inc. (“Denali”) received written notice from Takeda Pharmaceutical Company Limited (“Takeda”) of its decision to terminate the Collaboration Agreement (the “Agreement”), dated January 3, 2018, between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN).

View on SEC.gov

Browse all material agreements →

Denali Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001714899-26-000042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.